HEATAM Meetings 1,2 and 3


Professor David Wong reports on the third Heavy Tamponade meeting in Amsterdam and explains the background from the first and second events

Key Points

Is it toxic?

The second meeting was held in Viareggio, Italy 2006. Several new concepts were introduced. The Italians have been using "double tamponade", mixing F6H8 and silicone oil hoping to provide support for the superior and inferior fundus. This was highly controversial as the physicists and the model eye chamber studies indicated that double tamponade might not be possible; the resultant mixture acted as a single bubble. Another controversial aspect concerned Oxane HD. Nuclear magnetic resonance studies indicated that the agent may in fact not be a solution, in the sense that the mixture is not homogenous. The low solubility of alkene, RMN3 is such that the heavy oil solution probably readily separates into its constituent components. More worryingly, a new phenomenon that was not observed previously became apparent. Heavy oil can be sticky! This was very much the case with Oxane HD. Dr Dresp speculated that it might be due to the interaction of PFCL with the Oxane HD that led to the oil sticking. A straw poll was taken at this meeting asking who would use heavy oil? Having heard all of the presentation, half of the delegates indicated they would use Densiron and none of the delegates would choose Oxane HD. Both double tamponade and Oxane HD focused our minds as to how tamponade work. Previously, it has always been assumed for a tamponade agent to be effective, it needs to be lighter (or heavier) than aqueous. The fact that double tamponade and Oxane HD with its uncertain specific gravity both seemed to effective and acceptable, called into question our whole understanding of the tamponade effect. It is clear in some circumstances, a near total fill with oil was sufficient and compatible with anatomical success.

Two additional concepts dominated the meeting. Firstly, Prof Joussen's group did further work on other alkanes including F4H5, F4H6 and F4H8. To everyone's surprise, although the chemical structure of the substances were similar, the biocompatibility varied tremendously. It was concluded that the ratio between the number of carbon atoms with attached fluorine atoms to the number of carbon atoms with attached hydrogen atoms probably mattered. Equally, the size of the molecule might also be important. F4H5 is much better tolerated that F6H8. Secondly, Prof Kirchhof explained his concept of treating PVR with heavy tamponade. The intention is not so much to provide support for the inferior retina and close breaks located in the lower half of the fundus, but primarily to displace the proliferative milieu or the aqueous with its contained cytokines and growth factors to the superior retina where the retina is less affected by epiretinal membranes and where there may not be any retinal breaks present. This is very much the hypothesis and the basis for the multi-centre randomized trial of heavy silicone oil (Densiron-68) versus conventional silicone oil. The assumption is that Densiron would be more effective than conventional silicone oil for treating such cases of PVR with no retinal breaks within the top 4 clock hours of the fundus. Cologne was the initiating centre and Prof Joussen was the lead in this clinical trial.

Related Videos
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Giulia Corradetti, MD, discusses her presentation "Functional Microperimetric Correlates of OCT Structures Features in Intermediate AMD"
At this year's ARVO meeting, Paolo Silva, MD, presented data on Protocol AA on behalf of the DRCR Retina Network
Baruch Kuppermann, MD, PhD
At this year's ARVO meeting, Qinqin Zhang, PhD, presented a poster titled "A unified deep learning model for geographic atrophy segmentation: Adaptable to SS-OCT and SD-OCT data with multiple scan patterns."
Ash Abbey, MD, shares 36-month data from the GALE study of pegcetacoplan
© 2024 MJH Life Sciences

All rights reserved.